AG真人官方

LeMaitre Vascular President and Director David B. Roberts reported option exercises and subsequent open-market sales on 08/11/2025. The Form 4 shows Mr. Roberts acquiring shares upon exercise of previously granted stock options and selling multiple blocks of common stock the same day.

The filing lists option exercises generating 3,979, 123 and 6,713 shares at exercise prices of $37.29 and $35.48. On 08/11/2025 he sold blocks of 3,718, 384 and 6,713 shares at weighted average prices of $92.5337, $91.5484 and $92.3549, respectively. The filing shows beneficial ownership of 17,976 shares following these transactions. The Form is signed by Nathan Ulrich on 08/13/2025 as submitted.

Bridget A. Ross, a director of LeMaitre Vascular (LMAT), reported exercising 2,500 vested stock options on 08/08/2025 with an exercise price of $37.29, and concurrently selling 2,500 common shares at $94.00 per share. The option exercised was fully vested and had an expiration date of 12/02/2025. The sequence increased her direct holdings to 5,416 shares then, after the sale, left her with 2,916 shares of common stock beneficially owned.

John A. Roush, a director of LeMaitre Vascular (LMAT), exercised stock options to acquire 7,500 common shares at an exercise price of $37.29 on 08/08/2025 and 08/11/2025, as reported in Table II. The form states these option exercises converted derivative holdings into common stock.

Roush also sold a total of 7,500 shares across transactions on 08/08/2025 and 08/11/2025 at reported weighted-average prices of $93.4872, $92.783 and $91.8181, with execution ranges between $91.38 and $94.00. Following these transactions, the reporting person beneficially owned 2,916 shares of LeMaitre Vascular.

LeMaitre Vascular, Inc. (LMAT) filed a Form 144 proposing the sale of 976 common shares through Morgan Stanley Smith Barney LLC on 08/12/2025 on NASDAQ, with an aggregate market value of $90,553.28. The notice indicates 22,637,522 shares outstanding, so the position is a very small fraction of the company.

The 976 shares were acquired from the issuer as a mix of restricted stock and performance shares across five lots on dates in December 2024 and March 8, 2025 (198, 205, 201, 171, and 201 shares, which total 976). The filer reports no securities sold in the past three months and certifies they have no undisclosed material adverse information about the issuer.

LeMaitre Vascular (LMAT) filed a Form 144 reporting a proposed sale of 6,561 common shares through Morgan Stanley Smith Barney LLC on the NASDAQ with an aggregate market value of $607,229.74. The filing lists 22,637,522 shares outstanding and an approximate sale date of 08/11/2025. The securities were acquired by a stock option exercise on 08/11/2025 with payment in cash.

The filing also discloses a recent sale by JOHN ADAM ROUSH of 939 shares on 08/08/2025 for $87,784.39. The notice includes the standard representation that the seller is not aware of any undisclosed material adverse information about the issuer.

LeMaitre Vascular (LMAT) filed a Form 144 reporting a proposed sale of 10,815 common shares on NASDAQ with an aggregate market value of $999,173.07. The form states these shares equal roughly 0.048% of the 22,637,522 shares outstanding. The securities were acquired and are being sold on 08/11/2025 through a stock option exercise, with payment in cash, and the sale is to be executed through Morgan Stanley Smith Barney LLC. The filing notes no securities sold in the past three months by the selling person and includes the filer鈥檚 representation that they are unaware of any undisclosed material adverse information.

LeMaitre Vascular insider sale summary: George W. LeMaitre, who serves as Chairman and CEO and is a company director, reported a sale of 100,000 shares of LeMaitre Vascular Inc. (LMAT) on 08/06/2025. The sale was executed under a pre-established 10b5-1(c) trading plan adopted on 03/10/2025 and was carried out in multiple trades at a weighted average price of $93.5053, with individual trades ranging from $93.03 to $94.00. After the reported transaction, the reporting person beneficially owned 1,727,003 shares. The filer notes willingness to provide full trade-level details on request. No derivative transactions were reported on this Form 4.

LeMaitre Vascular (LMAT) submitted a Form 144 reporting a proposed sale of 939 shares of common stock with an aggregate market value of $87,784.39. The notice names Morgan Stanley Smith Barney LLC as broker and lists the approximate sale date as 08/08/2025 on NASDAQ, and shows 22,637,522 shares outstanding.

The filing states the securities were acquired on 08/08/2025 by a stock option exercise from the issuer and paid in cash. The section for securities sold in the past three months is marked "Nothing to Report". The form includes the standard attestation that the seller does not possess undisclosed material adverse information and references Rule 144 disclosure requirements.

LeMaitre Vascular, Inc. Form 144 reports a proposed sale of 2,500 common shares on NASDAQ through Morgan Stanley Smith Barney LLC with an aggregate market value of $235,000 and an approximate sale date of 08/08/2025. The filing lists 22,637,522 shares outstanding, showing the reported sale is a very small fraction of the companys outstanding stock.

The securities-to-be-sold were recorded as acquired by a stock option exercise on 08/08/2025 with payment in cash. The filing also discloses a prior sale by Bridget A Ross of 3,750 shares on 05/12/2025 for $312,000. Several filer identification fields (for example Filer CIK and Filer CCC) are not populated in the provided text. The signer affirms no undisclosed material adverse information.